Warner-Lambert Company

Henry Grant Morrison, Ii

David Andrew Coates

Zheng Jane Li

Joseph Francis Krzyzaniak

Karen Sue Gushurst

Aeri Park

Stephen Robert Byrn

Petinka Ivanova Vlahova

Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&#x3b2;,&#x3b4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Novel crystalline forms of &lsqb;R-(R*,R*)&rsqb;-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-&lsqb;(phenylamino)carbonyl&rsqb;-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.

Crystalline forms of &lsqb;R-(R*,R*)&rsqb;-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-&lsqb;(phenylamino)carbonyl&rsqb;-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Growing community of inventors

Lafayette, IN, United States of America

Henry Grant Morrison, Ii